Pain drugmaker Latigo Biotherapeutics went public Thursday, raising more than a third of a billion dollars to fuel its work developing new, non-opioid medicines. The Los Angeles-area biotechnology company is selling 19.2 million shares at $18 apiece, which should result in gross proceeds of $345.6 million. Joining Latigo on Thursday was cancer-focused BlossomHill Therapeutics, which priced almost 9.4 million shares at $16 each for gross proceeds of $150 million. This year has seen a significant uptick in large biotech IPOs, with Latigo being the 14th to secure $250 million or more. Eli Lilly is in this space, too, having bought pain specialist SiteOne Therapeutics in a deal worth up to $1 billion.